Trial Profile

A Pivotal, Phase III Study of INOpulse for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 09 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nitric oxide (Primary)
Indications Pulmonary fibrosis; Pulmonary hypertension
Focus Registrational; Therapeutic Use
Acronyms REBUILD
Sponsors Bellerophon Therapeutics

Most Recent Events

01 Dec 2020 According to a Bellerophon Therapeutics media release, the company announced the dosing of the first patient in this study. Topline results are expected in 2022.
01 Dec 2020 Status changed from planning to recruiting, according to a Bellerophon Therapeutics media release.
23 Nov 2020 According to a Bellerophon Therapeutics media release, the company expect to enroll first patient shortly.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com